Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

January 11, 2024

https://www.globenewswire.com/news-release/2024/01/11/2807912/0/en/Elicio-Therapeutics-Announces-First-Patient-Dosed-in-Randomized-Phase-2-Pancreatic-Cancer-Study.html

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq:ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).

Read more at globenewswire.com

Related news for (ELTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.